Merck Sharp + Dohme Corp.

Lycera Corporation

Merck Patent Gmbh

Merck Canada Inc.

Yuan Liu

Brian M Andresen

Neville J Anthony

Thomas Daniel Aicher

Kun Liu

Kenneth Jay Barr

Nunzio Sciammetta

Catherine M White

Matthew H Daniels

William L Thomas

Timothy J Guzi

Michael D Altman

Thomas Allen Miller

Stephane L Bogen

Alan B Northrup

Gerald Wayne Shipps, Jr

Michelle R Machacek

Manami Shizuka

Matthew Ernst Voss

John Michael Ellis

Ronald J Doll

Malcolm MacCoss

Kin-Ming Lo

Chad A VanHuis

Vladimir Simov

John K MacLean

Corey E Bienstock

Blair T Lapointe

Craig R Gibeau

Yaolin Wang

Latha G Nair

Weidong Pan

Kaleen Konrad Childers

Yuan Tian

Eric Thomas Romeo

Hyun Chong Woo

Yao Ma

Brian Robert Lahue

Margarita Kirova-Snover

Maria Emilia Di Francesco

Daniel Guay

Jeffrey Charles Way

Ryan D Otte

Andrew M Haidle

Michael Hale Reutershan

Kenneth L Arrington

Qiaolin Deng

Bheemashankar A Kulkarni

Jonathan B Grimm

Liping Wang

Benjamin Wesley Trotter

Brandon Mitsuo Taoka

Anthony Donofrio

Kerrie Spencer

Joel S Robichaud

Brendan O'Boyle

Dilrukshi Vitharana

Byron Dubois

Amin Nomeir

Giovanna Scapin

Wesley B Trotter

Danny J Hicklin

Marie-Eve Lebrun

Mark A McCoy

Diane Rindgen

W Bent Clayton

The invention provides certain bicylic heterocyclic compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X, X, R, R, R, R4, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT. 

Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease

The invention provides certain bicyclic heterocyclic compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X, X, R, R, R, R, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT. 

The invention provides certain benzoxazine compounds of the Formula (I) or pharmaceutically acceptable salts thereof wherein R, R, R, R, R, R, R, R, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT. 

Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease

The invention provides certain thiazole-substituted aminoheteroaryl compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X, X, X, X, Y, Y, Y, Y, and Rare as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk). 

Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors

The invention provides certain benzoxazine compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT. 

2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease

The invention provides certain thiazole-substituted aminopyridine compounds of the Formula (I) (I) or pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, C, and the subscript t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk). 

Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors

The present invention provides a compound of Formula I (The formula should be inserted here) as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same. 

Substituted piperidines as HDM2 inhibitors

The present invention provides a compound of Formula 1 as described herein or a pharmaceutically acceptable salt, solvate or ester thereof. The compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same.

Substituted piperidines that increase p53 activity and the uses thereof

The invention provides certain amino-pyridine-containing compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, R, R, and n are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase. 

Amino-pyridine-containing spleen tyrosine kinase (SYK) inhibitors

The present invention provides an isolated IL-6 antagonist including an antibody variable region that prevents IL-6 from binding to gp130. The present invention also provides compositions and methods for treating IL-6 related diseases based on the IL-6 antagonists of the invention.

Antibodies to interleukin-6

Growing community of inventors

Billerica, MA, United States of America

Yuan Liu